Ignite Creation Date:
2025-12-25 @ 4:59 AM
Ignite Modification Date:
2026-01-24 @ 1:21 PM
Study NCT ID:
NCT01787318
Status:
COMPLETED
Last Update Posted:
2016-04-14
First Post:
2013-01-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Effect of the InsuPatch on Automated Closed-loop Glucose Control in Type 1 Diabetes
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['EARLY_PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 10}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-04', 'completionDateStruct': {'date': '2015-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-04-13', 'studyFirstSubmitDate': '2013-01-16', 'studyFirstSubmitQcDate': '2013-02-05', 'lastUpdatePostDateStruct': {'date': '2016-04-14', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2013-02-08', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Peak Post-Prandial Glucose Excursions', 'timeFrame': '48 hours', 'description': 'Peak post-prandial plasma glucose excursions after breakfast, lunch, and dinner on days #2 and #3. One day with InsuPatch activated and one day without InsuPatch activated'}], 'secondaryOutcomes': [{'measure': 'Total Area Under Curve of the meal-related glucose excursion over target', 'timeFrame': '48 hours'}, {'measure': 'Nadir glucose levels following the meals', 'timeFrame': '48 hours'}, {'measure': 'Mean 24 hour glucose levels', 'timeFrame': '48 hours'}, {'measure': 'Mean daytime and nighttime glucose levels', 'timeFrame': '48 hours'}, {'measure': 'Peak post-prandial insulin levels following meals', 'timeFrame': '48 hours'}, {'measure': 'Area Under Curve meal-related insulin excursion following meals', 'timeFrame': '48 hours'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ['Type 1 Diabetes']}, 'descriptionModule': {'briefSummary': 'This research study designed to look at how well adolescents\' and young adults\' blood sugars can be controlled with a "closed loop artificial pancreas" using a continuous glucose sensor, an insulin pump, and a computer program that automatically determines how much insulin to give based on the glucose level. The investigators will also study the effect of wearing a small heating patch, the InsuPatch, at the site of insulin infusion, on the ability of the closed loop system to control the blood sugar levels and to reduce the rise in glucose levels after meals.', 'detailedDescription': 'This is an open-label, single-center, randomized crossover study evaluating the performance of a closed-loop (CL) insulin delivery system using a subcutaneous glucose sensor and an external insulin pump comparing the peak post-prandial glucose levels and the post-prandial glucose AUC during either CL control alone or CL control with the InsuPatch in an inpatient hospital research unit (HRU) setting. The closed loop visit consists of approximately 67 hours over 4 days and 3 nights.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '40 Years', 'minimumAge': '12 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. age 12-40 years\n2. clinical diagnosis of type 1 diabetes\n3. duration of type 1 diabetes ≥ 1 year\n4. HbA1c ≤ 9 %\n5. Treated with pump therapy for at least 3 months\n6. Body weight \\> 40 kg\n\nExclusion Criteria:\n\n1. Insulin resistant (defined as requiring \\> 1.5 units/kg/day at time of study enrollment\n2. Presence of any medical or psychiatric disorder that may interfere with subject safety or study conduct\n3. Use of any medications (besides insulin) known to blood glucose levels, including oral or other systemic glucocorticoid therapy. Inhaled, intranasal, or rectal corticosteroid use is allowed along as not given within 4 weeks of admission. Use of topical glucocorticoids is allowable as long as affected skin area does not overlap with study device sites. Subjects using herbal supplements will be excluded, due to the unknown effects of these supplements on glucose control\n4. History of poor wound healing, heat sensitivity, or diminished skin integrity.\n5. History of hypoglycemic seizure within last 3 months\n6. Anemic (low hematocrit), or evidence of renal insufficiency (elevated serum creatinine)\n7. Female subjects who are pregnant, lactating, or unwilling to be tested for pregnancy\n8. Subjects unable to give consent / permission / assent'}, 'identificationModule': {'nctId': 'NCT01787318', 'acronym': 'IPCL', 'briefTitle': 'Effect of the InsuPatch on Automated Closed-loop Glucose Control in Type 1 Diabetes', 'organization': {'class': 'OTHER', 'fullName': 'Yale University'}, 'officialTitle': 'Effect of the Insupatch on Automated Closed-loop Glucose Control in Type 1 Diabetes', 'orgStudyIdInfo': {'id': 'HIC # 1208010682'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ePID closed loop system using Insupatch', 'description': 'Insupatch activated at mealtimes', 'interventionNames': ['Device: ePID closed loop system', 'Device: InsuPatch']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'ePID closed loop system without InsuPatch', 'description': 'InsuPatch will not be activated at mealtimes', 'interventionNames': ['Device: ePID closed loop system']}], 'interventions': [{'name': 'ePID closed loop system', 'type': 'DEVICE', 'description': 'Insulin pump controlled by closed loop unit and algorithm', 'armGroupLabels': ['ePID closed loop system using Insupatch', 'ePID closed loop system without InsuPatch']}, {'name': 'InsuPatch', 'type': 'DEVICE', 'description': 'device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site', 'armGroupLabels': ['ePID closed loop system using Insupatch']}]}, 'contactsLocationsModule': {'locations': [{'zip': '06520', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Yale University School of Medicine', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}], 'overallOfficials': [{'name': 'Stuart Weinzimer, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Yale University'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Yale University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}